Payment overview · 2025
General Payments
$537.15
29 reported records · 14 companies
Healthcare provider profile · identity verified
Buddy Buford Stokes, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · DANVILLE, VA · NPI 1003172313
Verified facts
What the public records show
CMS Open Payments records show Buddy Buford Stokes, D.O. received $537.15 in general payments during 2025 across 29 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $116.44 | 21.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $83.59 | 15.6% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$59.46 | 11.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.39 | 10.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.48 | 9.6% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $42.00 | 7.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.13 | 4.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.23 | 3.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.13 | 3.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.35 | 3.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.38 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.33 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.81 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.43 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $537.15 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $116.44 | 7 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $59.46 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.39 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.98 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.76 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.61 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tramadol Hcl | Tramadol Hcl | 663 | 140 |
| Alprazolam | Alprazolam | 479 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 193 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 438 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 147 |
| Gabapentin | Gabapentin | 346 | 120 |
| Losartan Potassium | Losartan Potassium | 321 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 299 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 89 |
| Pregabalin | Pregabalin | 238 | 69 |
| Omeprazole | Omeprazole | 197 | 74 |
| Lisinopril | Lisinopril | 193 | 71 |
| Oxycodone Hcl | Oxycodone Hcl | 186 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 180 | 51 |
| Furosemide | Furosemide | 170 | 85 |
| Montelukast Sodium | Montelukast Sodium | 167 | 64 |
| Trazodone Hcl | Trazodone Hcl | 166 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 59 |
| Meloxicam | Meloxicam | 158 | 54 |
| Potassium Chloride | Potassium Chloride | 155 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 60 |
| Quetiapine Fumarate | Quetiapine Fumarate | 149 | 42 |
| Temazepam | Temazepam | 132 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 38 |
| Metformin Hcl | Metformin Hcl | 113 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 44 |
| Eliquis | Apixaban | 106 | 41 |
| Clonazepam | Clonazepam | 100 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 39 |
| Simvastatin | Simvastatin | 97 | 34 |
| Ozempic | Semaglutide | 96 | 23 |
| Sertraline Hcl | Sertraline Hcl | 94 | 37 |
| Clonidine Hcl | Clonidine Hcl | 89 | 43 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 89 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 35 |
| Ondansetron Odt | Ondansetron | 84 | 21 |
| Jardiance | Empagliflozin | 82 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 30 |
| Allopurinol | Allopurinol | 78 | 29 |
| Carvedilol | Carvedilol | 78 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 39 |
| Mounjaro | Tirzepatide | 76 | 17 |
| Methocarbamol | Methocarbamol | 73 | 42 |
| Lorazepam | Lorazepam | 71 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 24 |
| Midodrine Hcl | Midodrine Hcl | 70 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 39 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 68 | 13 |
| Diazepam | Diazepam | 66 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 23 |
| Myrbetriq | Mirabegron | 63 | 14 |
| Ezetimibe | Ezetimibe | 62 | 27 |
| Memantine Hcl | Memantine Hcl | 59 | 23 |
| Levofloxacin | Levofloxacin | 56 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 21 |
| Donepezil Hcl | Donepezil Hcl | 53 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 22 |
| Azithromycin | Azithromycin | 50 | 35 |
| Glimepiride | Glimepiride | 50 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 17 |
| Buspirone Hcl | Buspirone Hcl | 48 | 24 |
| Fluconazole | Fluconazole | 48 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 41 |
| Glipizide | Glipizide | 47 | 17 |
| Bumetanide | Bumetanide | 46 | 24 |
| Famotidine | Famotidine | 46 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 43 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 14 |
| Bupropion Xl | Bupropion Hcl | 42 | 13 |
| Linzess | Linaclotide | 41 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 15 |
| Methylprednisolone | Methylprednisolone | 38 | 27 |
| Mirtazapine | Mirtazapine | 38 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 15 |
| Sucralfate | Sucralfate | 37 | 14 |
| Farxiga | Dapagliflozin Propanediol | 35 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 13 |
| Promethazine Hcl | Promethazine Hcl | 34 | 13 |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | 13 |
| Atenolol | Atenolol | 33 | suppressed |
| Prednisone | Prednisone | 33 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 25 |
| Meclizine Hcl | Meclizine Hcl | 31 | 17 |
| Spironolactone | Spironolactone | 31 | 20 |
| Trulicity | Dulaglutide | 30 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 15 |
| Entresto | Sacubitril/Valsartan | 28 | 14 |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 21 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | 12 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Topiramate | Topiramate | 25 | 12 |
| Celecoxib | Celecoxib | 24 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Nystatin | Nystatin | 21 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | 11 |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $537.15 · 29 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, Dexcom G6 Transmitter, EVENITY, FARXIGA, INSPIRE, Kerendia, Korlym, MOUNJARO, OFEV, REPATHA, REXULTI, SYMPLICITY G3, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error